Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists.
Lanier G, Sankholkar K, Aronow WS.
Am J Ther · review; journal article · DOI 10.1097/mjt.0b013e31824a0ed7 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för azilsartan. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
13 träffarWhat can we expect from the binding characteristics of azilsartan, a newly available angiotensin II blocker, in hypertension?
Tamura K, Ohsawa M, Kanaoka T, Maeda A, Azushima K, Uneda K, Wakui H, Azuma K, Tsurumi-Ikeya Y, Umemura S.
Hypertens Res · comment; journal article · DOI 10.1038/hr.2012.166Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan.
Miura S, Okabe A, Matsuo Y, Karnik SS, Saku K.
Hypertens Res · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/hr.2012.147[Azilsartan: a new angiotensin receptor blocker].
Rakugi H, Enya K.
Nihon Rinsho · review; journal article; english abstractClinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.
Shuster JE, Bleske BE, Dorsch MP.
Vasc Health Risk Manag · review-article; review; journal article · DOI 10.2147/vhrm.s22583[In vitro and in vivo pharmacological profiles of a novel angiotensin type 1-receptor blocker, azilsartan].
Kusumoto K.
Nihon Yakurigaku Zasshi · review; journal article · DOI 10.1254/fpj.139.236Critical evaluation of the efficacy and tolerability of azilsartan.
De Caterina AR, Harper AR, Cuculi F.
Vasc Health Risk Manag · review-article; review; journal article · DOI 10.2147/vhrm.s22589Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
Kurtz TW, Kajiya T.
Vasc Health Risk Manag · review-article; review; journal article · DOI 10.2147/vhrm.s22595Assessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1.
Weltman R, Brands CM, Corral E, Desmares-Koopmans MJ, Migchielsen MH, Oudhoff KA, de Roode DF.
Chemosphere · research support, non-u.s. gov't; journal article · DOI 10.1016/j.chemosphere.2012.01.053Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.
Rakugi H, Enya K, Sugiura K, Ikeda Y.
Hypertens Res · comparative study; research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1038/hr.2012.8Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats.
Zhao M, Li Y, Wang J, Ebihara K, Rong X, Hosoda K, Tomita T, Nakao K.
Diabetes Obes Metab · research support, non-u.s. gov't; journal article · DOI 10.1111/j.1463-1326.2011.01471.xMolecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker.
Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW.
J Hypertens · research support, non-u.s. gov't; journal article; research support, n.i.h., extramural · DOI 10.1097/hjh.0b013e32834c46fdAzilsartan: a newly approved angiotensin II receptor blocker.
Lam S.
Cardiol Rev · review; journal article · DOI 10.1097/crd.0b013e31822e9ba3